JustAnswer sees surge in GLP-1 and weight loss peptide questions

Nearly one in three peptide questions on JustAnswer in 2026 also mentioned GLP-1s or weight loss, up sharply from 2024 as consumers increasingly ask about dosing, mixing and injections. The shift comes as regulators and researchers scrutinize peptide safety, labeling and compounding.

Why it matters: - Consumer questions are moving from curiosity to hands-on use, raising the stakes around dosing, mixing and injection safety. - The spike also shows how GLP-1 weight-loss drugs and experimental peptides are converging in consumer search and advice-seeking behavior. - The trend lands as the FDA weighs whether some currently unapproved peptides should be eligible for pharmacy compounding.

What happened: - JustAnswer found that 31% of peptide-related questions submitted in 2026 through August also mentioned GLP-1s or weight loss. - That share was 24% in 2025 and 17% in 2024, an 81% increase over two years. - The analysis drew on thousands of consumer questions submitted to the online platform connecting people with licensed professionals. - Dr. Cuilan Li, a physician on JustAnswer, said the questions have shifted from asking what a peptide is to asking how many units to draw into a syringe.

The details: - Consumers now ask how to mix peptides, how much to inject, how often to inject and how to reconstitute a vial. - Many questions focus on whether peptides can be combined with other medications safely. - Consumers also ask about stacking multiple peptides, whether oral or injectable versions work better and whether peptide use is safe before or after surgery. - Questions increasingly link peptides with weight loss, including how they differ from prescription GLP-1 medications. - Users ask whether tirzepatide and semaglutide are peptides and whether they can switch from FDA-approved drugs such as Ozempic, Wegovy, Mounjaro and Zepbound to compounded versions of semaglutide or tirzepatide. - The article distinguishes FDA-approved medications, compounded medications and unapproved peptides sold through research-use-only or direct-to-consumer channels as non-interchangeable products with different regulatory review and quality controls. - Gallup’s latest national survey found that about 11% of U.S. adults currently take GLP-1 medications for weight loss, up from 3% in 2024. - A September preprint analysis of de-identified clinical records covering 15.2 million patients identified 1,039 patients with documented BPC-157 use. - Newly confirmed BPC-157 users increased 33-fold between the first quarters of 2020 and 2026. - Across the 2024-2026 period studied, BPC-157 was the most frequently mentioned specific peptide in JustAnswer questions, followed by TB-500 and collagen peptides. - Other recurring terms included GHK, GHK-Cu, CJC, CJC-1295, ipamorelin, NAD, tesamorelin and retatrutide. - Questions also covered cancer treatment, other diagnosed conditions, pregnancy, attempts to conceive and whether to stop peptides before surgery. - Consumers also asked about recovery from injuries involving tendons or ligaments, skin, hair and wrinkles, muscle growth, testosterone and growth-hormone-related peptides. - Dr. Li said many consumers first learn about these products through social media or online sources, while human data and established guidance on dosing, administration and safety remain limited for many experimental peptides.

Between the lines: - The data suggests consumers are treating peptides less like fringe wellness products and more like active self-directed treatments. - The overlap with GLP-1s also points to confusion between regulated drugs and products that may not have the same labeling or evidence base. - Safety concerns are not abstract: WIRED recently reported that testing of peptide products sold at New York convenience stores found the products did not contain the active ingredients listed on their labels.

What's next: - The FDA’s decision on whether to expand compounding for certain unapproved peptides will shape access, labeling and oversight. - If GLP-1 use keeps rising, consumer questions about peptide alternatives, compounding and injection technique are likely to keep growing. - JustAnswer will continue routing health-related peptide questions to licensed professionals on its platform.

The bottom line: - More consumers are trying to self-navigate peptides for weight loss and beyond, but the questions are getting more clinical while the evidence and regulation remain uneven.

Learn more about how JustAnswer works